Copyright
©The Author(s) 2019.
World J Gastroenterol. Feb 21, 2019; 25(7): 789-807
Published online Feb 21, 2019. doi: 10.3748/wjg.v25.i7.789
Published online Feb 21, 2019. doi: 10.3748/wjg.v25.i7.789
Table 5 Results of the CERESTIAL trial[45]
Cabozantinib (n = 470) | Placebo (n = 237) | HR, P-value | |
OS (M, 95%CI) | 10.2 (9.1-12.0) | 8.0 (6.8-9.4) | HR 0.76 (95%CI 0.63-0.92) P = 0.0049 |
PFS (M, 95%CI) | 5.2 (4.0-5.5) | 1.9 (1.9-1.9) | HR 0.44 (95%CI 0.36-0.52) P < 0.0001 |
Objective response (investigator assessed, RECIST 1.1) | |||
CR (%) | 0 | 0 | |
PR (%) | 4 | 0.4 | |
SD (%) | 60 | 33 | |
PD (%) | 21 | 55 | |
NE (%) | 15 | 11 | |
ORR (%, 95CI) | 4 (2.3-6.0) | 0.4 (0.0-2.3) | P = 0.0086 |
DCR (%) | 64 | 33.4 |
- Citation: Kudo M. Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond. World J Gastroenterol 2019; 25(7): 789-807
- URL: https://www.wjgnet.com/1007-9327/full/v25/i7/789.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i7.789